Stephanie L Quinn

US Patent:

20080188449, Aug 7, 2008

Filed:

Nov 15, 2005

Appl. No.:

11/667696

Inventors:

Craig M. Crews - New Haven CT, US
Stephanie J. Quinn - Hope Valley RI, US
Stefan Somlo - Westport CT, US
Dayne Okuhara - Westford MA, US

Assignee:

Yale University - New Haven CT

International Classification:

A61K 31/585
A61P 13/12
C12N 5/02
C12Q 1/02

US Classification:

514175, 435375, 435 29

Abstract:

In certain aspects, the invention relates to use of PKD2 agonists, such as triptolide and triptolide derivatives, to regulate calcium release. In other aspects, the invention relates to use of PKD2 agonists to treat or aid in the treatment of any condition in which a calcium channel, such as the gene product of PKD 1 and/or PKD2, is mutated; calcium signaling is abnormal; or both, such as polycystic kidney disease.

US Patent:

20080063601, Mar 13, 2008

Filed:

Mar 12, 2007

Appl. No.:

11/716980

Inventors:

Stefan Somlo - Westport CT, US
Craig Crews - New Haven CT, US
Stephanie Quinn - Hope Valley RI, US
Dayne Okuhara - Lexington MA, US

Assignee:

Yale University - New Haven CT

International Classification:

A61K 31/58
A61K 49/00
A61P 13/12
C07K 7/08
C12Q 1/02

US Classification:

424009200, 435029000, 514171000, 514172000, 530326000

Abstract:

Described herein are therapeutic strategies (methods and compositions) useful for treating conditions in which cilia are affected and which manifest with cysts and/or fibrosis, such as conditions in which the kidney, pancreas, liver and/or spleen are affected and contain cysts. Particular embodiments described herein are therapeutic strategies in which PC-2 agonists, particularly agonists (calcium channel agonists) that target PC-2 directly and/or selectively, are administered to individuals with mutations in PKD1, in order to alter the course of polycystic kidney disease, particularly ADPKD. In specific embodiments, the invention relates to use of PC-2 agonists triptolide and triptolide derivatives to regulate calcium release. In other aspects, the invention relates to use of PC-2 agonists to treat or aid in the treatment of any condition in which a calcium channel, such as the gene product of PKD1 and/or PKD2, is mutated; calcium signaling is abnormal; or both.